OpenClaim

Nelarabine Side Effects

The most commonly reported side effects of nelarabine include febrile neutropenia, neurotoxicity, and sepsis, based on 949 FDA adverse event reports from 2006 to 2025. 6.3% of reports found the drug to be ineffective.

#1 Reported: Febrile NeutropeniaAll side effects ↓Top Co-Medication: MethotrexateDrug interactions ↓56% of Reports Are AdultDemographics ↓

Nelarabine side effects

Percentages show how often each reaction appears relative to total reports for nelarabine.

1
Febrile Neutropenia7.5%71
2
Drug Ineffective6.3%60
3
Neurotoxicity5.8%55
4
Sepsis5.4%51
5
Myelopathy5.4%51
6
Neuropathy Peripheral5.2%49
7
Muscular Weakness5.2%49
8
Peripheral Sensory Neuropathy5.1%48
9
Off Label Use5.0%47
10
Neutropenia4.5%43
11
Guillain-barre Syndrome3.9%37
12
Thrombocytopenia3.8%36
13
Respiratory Failure3.7%35
14
Hypoaesthesia3.5%33
15
Anaemia3.4%32

These are voluntary reports and do not establish that nelarabine caused these reactions.

Report severity

96.4%Serious915 reports
33.8%Hospitalizations321 reports
21.7%Fatal206 reports

Seriousness is determined by the reporter, not by OpenClaim.

Nelarabine drug interactions

Other drugs that appear in adverse event reports alongside nelarabine. Drugs flagged as a suspected cause appear in the first column. Drugs taken at the same time but not suspected appear in the second.

Also suspected

1
Methotrexate36.5%346
2
Cyclophosphamide33.3%316
3
Vincristine-sulfate29.3%278
4
Cytarabine28.3%269
5
Dexamethasone23.4%222
6
Mercaptopurine16.8%159
7
Etoposide16.6%158
8
Doxorubicin-hydrochloride11.5%109
9
Asparaginase11.0%104
10
Pegaspargase10.6%101
11
Daunorubicin9.4%89
12
Fludarabine-phosphate6.3%60
13
Prednisone6.0%57
14
Venetoclax5.8%55
15
Daratumumab3.8%36

Taken alongside

1
Methotrexate13.0%123
2
Cytarabine12.4%118
3
Cyclophosphamide12.1%115
4
Dexamethasone11.6%110
5
Vincristine-sulfate11.2%106
6
Etoposide8.0%76
7
Prednisone6.2%59
8
Mercaptopurine6.1%58
9
Granisetron5.5%52
10
Fludarabine-phosphate5.4%51
11
Sulfamethoxazole5.1%48
12
Ondansetron4.8%46
13
Trimethoprim4.8%46
14
Doxorubicin-hydrochloride4.6%44
15
Hydrocortisone3.8%36

Co-occurrence in adverse event reports does not establish a drug interaction. Patients often take multiple medications, and these lists reflect prescribing patterns rather than causal relationships. Consult a healthcare provider about potential drug interactions.

Who reports nelarabine side effects

25.3% of nelarabine adverse event reports involve female patients and 59.6% involve male patients. The largest age group is adult at 56%. These figures reflect who reports side effects, not underlying risk.

Sex

Female25.3%
Male59.6%
Unknown15.1%

Age group

< 21.0%
2–1121.3%
12–1717.9%
18–6456.0%
65+3.8%

What is nelarabine used for

Conditions and purposes for which patients were taking nelarabine when the adverse event was reported.

Acute Biphenotypic LeukaemiaAcute LeukaemiaAcute Lymphocytic LeukaemiaAcute Lymphocytic Leukaemia RecurrentAdult T-cell Lymphoma/leukaemiaAcute LeukaemiaAcute Lymphocytic LeukaemiaAcute Lymphocytic Leukaemia RecurrentAcute Lymphocytic Leukaemia RefractoryAcute Myeloid LeukaemiaAdult T-cell Lymphoma/leukaemiaAllogenic Stem Cell TransplantationBone Marrow Conditioning RegimenBone Marrow TransplantCentral Nervous System Lymphoma

Showing 15 of 70 indications

Nelarabine brand names and reporting trend

Nelarabine is sold under the brand name Nelarabine.

Brand names

Nelarabine911

Quarterly reports (2006–2025)

20062010201520202025

An upward trend reflects increased FAERS reporting overall, not necessarily increased risk.

Taking nelarabine with another medication?

Ask OpenClaim about your specific drug combination. Get a sourced report using FDA data, drug labels, and medical literature.

Check my medications